Cash Flow Statement (Annual)
HALO / Halozyme Therapeutics, Inc. Cash Flow Statement shows changes in cash positions over time. Cash Flow Statement data includes Cash from Operating Activities (CFOP), Cash from Investing Activities, and Cash from Financing Activities.
All numbers are times 1,000 except per share units.
|Net Cash Provided By Used In Operating Activities|
|Net Income Loss||-58,361||-53,242||-19,770||-53,552||-83,479||-68,375||-32,231||-103,023||62,971|
|Adjustments To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities|
|Share Based Compensation||4,526||4,866||5,570||8,349||9,538||15,274||20,838||25,585||30,670|
|Depreciation Depletion And Amortization||1,444||1,508||1,096||1,079||1,227||1,762||1,677||2,410||2,200|
|Amortization Of Financing Costs||-||-||0||9||156||2,025||1,243||2,896||1,761|
|Paid In Kind Interest||-||-||-||-||-||0||879||13,184||0|
|Accretion Amortization Of Discounts And Premiums Investments||-||-||0||0||-1,116||-1,457||-879||-552||303|
|Gain Loss On Sale Of Property Plant Equipment||-3||-14||2||-7||0||-233||-8||-8||-46|
|Increase Decrease In Deferred Revenue||11,034||-2,389||-17,210||2,962||9,297||1,490||-1,411||701||22,759|
|Recognition Of Deferred Revenue||-||-||-||-||-||5,554||5,789||9,304||6,512|
|Straight Line Rent||-||-||-||-||-||-||276||370||185|
|Other Operating Activities Cash Flow Statement||-||-||-||-||-||-||0||0||-16|
|Increase Decrease In Operating Capital|
|Increase Decrease In Accounts Receivable||-3,021||-1,916||-66||13,441||-6,606||52||23,261||-16,730||6,453|
|Increase Decrease In Inventories||718||-966||374||2,103||3,499||236||3,083||5,134||-9,477|
|Increase Decrease In Prepaid Deferred Expense And Other Assets||-1,017||2,147||4,611||4,421||-1,959||265||15,774||-5,626||-2,035|
|Increase Decrease In Accounts Payable And Accrued Liabilities||-2,000||3,437||712||-3,263||7,889||-816||13,866||-244||15,629|
|Net Cash Provided By Used In Operating Activities Continuing Operations||-||-||-||-||-||-||-37,083||-50,383||134,053|
|Net Cash Provided By Used In Investing Activities|
|Payments To Acquire Available For Sale Securities||-||-||0||0||48,947||88,884||71,482||155,412||398,187|
|Proceeds From Sale Of Available For Sale Securities||-||-||0||0||3,375||57,301||79,730||81,783||235,805|
|Payments To Acquire Property Plant And Equipment||1,461||647||829||1,413||2,298||1,368||2,360||3,137||1,350|
|Net Cash Provided By Used In Investing Activities Continuing Operations||-||-||-||-||-||-||5,888||-76,766||-163,732|
|Net Cash Provided By Used In Financing Activities|
|Proceeds From Issuance Of Common Stock||38,174||59,965||0||81,477||0||107,713||0||0||134,874|
|Proceeds From Debt Net Of Issuance Costs||-||0||0||29,661||19,985||0||0||203,006||0|
|Repayments Of Secured Debt||-||-||-||-||-||0||0||54,250||15,995|
|Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options||-||-||-||-||5,079||6,788||13,098||1,865||12,776|
|Net Cash Provided By Used In Financing Activities Continuing Operations||-||-||-||-||-||-||13,098||150,621||131,655|
|Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect||-||-||-||-||-||-||-18,097||23,472||101,976|
|Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents||-||-||-||-||-||-||-||-||169,240|
Peers - Biological Products, Except Diagnostic Substances (Biotech) (2836)
APEN / Apollo Endosurgery Inc.
ARIA / ARIAD Pharmaceuticals, Inc.
AVIR / Aviragen Therapeutics, Inc.
AVXS / AveXis, Inc.
BOTA / Biota Pharmaceuticals, Inc.
CASI / CASI Pharmaceuticals, Inc.
CYTR / CytRx Corp.
EIGR / Eiger BioPharmaceuticals, Inc.
FENC / Fennec Pharmaceuticals Inc.
Related News Stories
Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning. (320-4)
Stocks were indicated to open lower on Thursday morning, though the S&P 500 hit an all-time high earlier in the week. Earnings season is all but over now and was quite strong, with more than 70% of the companies exceeding expectations. Despite the gains in the market, 2018 has been choppy, and investors have seen less reward in buying every dip than they had been used to in recent years. Many investors also are trying to decide how they want their investments positioned ahead of the midterm elections and given international trade concerns. (44-1)
The passing of singing great Aretha Franklin has focused attention on pancreatic cancer. Franklin, 76, succumbed to a neuroendocrine tumor of the pancreas. According to the National Cancer Institute (NCI), pancreatic cancer is relatively rare, with about 55,440 cases diagnosed annually, representing about 3.2 percent of new cancer cases. But each year, 44,330 Americans die from the disease, or about 7. (0-1)
Halozyme Therapeutics (NASDAQ:HALO) is a robust grower that is operating near its growth inflection. Most investment risks are now significantly deleveraged due to the increasing sales from the approved molecules. Despite that that the partnered products in commercialization are delivering meaningful sales, there are substantial unlocked values in the developing pipeline. In the past 52-week, the stock traded up by $4.
Halozyme Therapeutics (HALO - Free Report) came out with a quarterly loss of $0.16 per share versus the Zacks Consensus Estimate of a loss of $0.22. This compares to loss of $0.23 per share a year ago. These figures are adjusted for non-recurring items. (2-0)
as of ET